Skip to main content
Premium Trial:

Request an Annual Quote

McKesson to Distribute Atossa Specimen Kits for Breast Cancer Dx

NEW YORK (GenomeWeb News) – Atossa Genetics today said that McKesson Medical-Surgical will distribute and sell the firm's MASCT device and patient collection kits.

The device and kits are used in OB/GYN, primary care, and women's health clinics for non-invasive collection of breast fluid. The sample is then analyzed by an Atossa subsidiary with the firm's ForeCYTE Breast Health Test, which assesses future risk of breast cancer.

"Our agreement with McKesson Medical-Surgical is another important step forward in making the ForeCYTE test the standard of care in breast cancer risk assessment," Atossa Chairman, President, and CEO Steven Quay said in a statement. "With their extensive market presence, we look forward to providing physicians a much needed early warning system by detecting the earliest, reversible precursors of breast cancer."

Terms of the agreement were not disclosed.

Seattle-based Atossa has signed several distribution deals for the MASCT device and ForeCYTE test over the past year. Most recently, it signed up Thermo Fisher Scientific's Fisher HealthCare as a distributor.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.